Navigation Links
London researchers lead innovative new cancer treatment study

LONDON, ON An innovative treatment technology could give cancer patients new hope for survival. In an international study based at Lawson Health Research Institute and London Health Sciences Centre's London Regional Cancer Program (LRCP), scientists are testing a therapy with the potential to eradicate cancers previously thought to be incurable.

Many complications of cancer occur when it spreads from the original tumour to other areas of the body, such as the brain, liver, or lungs. At this point, the odds of survival are low. Traditional treatments, like chemotherapy, can sometimes slow down the disease, but not stop it.

Using stereotactic ablative radiotherapy, or "SABR," scientists believe they may have found a solution. SABR delivers very large, concentrated doses of radiotherapy to very precise areas, often with few side-effects.

In the newly launched COMET Trial, Dr. David Palma and his colleagues will assess SABR's impact on patient survival, side effects, and quality of life. Over the next four years, 99 patients in Canada and Europe will be randomized to receive either the SABR treatment or the standard-of-care treatment.

"This technology holds promise, in that we are using radiation to target cancers that would previously have been considered incurable," says Dr. Palma. "Although some centres have been using SABR for this purpose with promising results, the COMET study will allow us to see if it really provides a benefit for these patients."

"This trial will help establish the safety and benefit of advanced radiation techniques for the aggressive treatment of patients with a small number of sites of cancer spread," adds Dr. Glenn Bauman, Lawson Scientist and Chair/Chief of the Department of Oncology at LRCP. "Expanding the range of treatment options available and providing better cancer control for these patients are important goals of the trial."

The COMET trial is funded by the Ontario Institute for Cancer Research. In 2012, this Lawson-led study will extend to other collaborators in Ontario, British Columbia, and the Netherlands.

Dr. David Palma is a Scientist at Lawson and a Radiation Oncologist at London Health Sciences Centre's LRCP.


Contact: Sonya Gilpin
519-685-8500 x75852
Lawson Health Research Institute

Related biology news :

1. A London effort to develop point-of-care nanosensors for HIV diagnosis and monitoring
2. Imperial College London and NTU collaborate to offer joint Ph.D. programs in engineering and science
3. Kings College London signs agreement to strengthen Brazilian research links
4. Press registration is now open for EULAR 2011, May 25-28, London
5. Researcher to present discoveries on medical uses of ultrasound to London’s Royal Society
6. Researcher to present discoveries on medical uses of ultrasound to Londons Royal Society
7. Media invitation: Pioneer of organ-on-a-chip technology to speak at Imperial College London
8. NC State researchers get to root of parasite genome
9. Researchers find animal with ability to survive climate change
10. Researchers find an essential gene for forming ears of corn
11. Researchers note differences between people and animals on calorie restriction
Post Your Comments:
(Date:10/29/2015)... , Oct. 29, 2015  The J. Craig ... report titled, "DNA Synthesis and Biosecurity: Lessons Learned and ... Department of Health and Human Services guidance for synthetic ... 2010. --> --> ... also has the potential to pose unique biosecurity threats. ...
(Date:10/29/2015)... OXFORD, Connecticut , October 29, 2015 /PRNewswire/ ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet announces that StackCommerce, a leading ... will be featuring the Wocket® smart wallet on ... NXTD ) ("NXT-ID" or the "Company"), a ...
(Date:10/27/2015)... Oct. 27, 2015 Synaptics Inc. (NASDAQ: SYNA ... that Google has adopted the Synaptics ® ClearPad ... to power its newest flagship smartphones, the Nexus 5X ... --> --> Synaptics ... provide strategic collaboration in the joint development of next ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased to ... presentations offered in symposia, oral sessions, workshops, awards, and posters. The core ... of applications such as, but not limited to, biotechnology, biomedical, drug discovery, environmental, ...
(Date:11/26/2015)... CHESHAM , England , November 26, ... Lightpoint Medical, an innovative medical device company specializing in ... Euro grant from the European Commission as part of the ... enabling the company to carry out a large-scale clinical trial ... -->      (Logo: , ...
(Date:11/25/2015)... 2015 2 nouvelles études permettent d ... les différences entre les souches bactériennes retrouvées dans la plaque ... êtres humains . Ces recherches  ouvrent une nouvelle ... en charge efficace de l,un des problèmes de ... .    --> 2 nouvelles études permettent ...
(Date:11/25/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... CEO of Neurocrine Biosciences, will be presenting at the ... New York . .   ... 5 minutes prior to the presentation to download or ... will be available on the website approximately one hour ...
Breaking Biology Technology: